Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

Toll-Like Receptor 8-Mediated Reversal of CD4 ⁺ Regulatory T Cell Function

Guangyong Peng, Zhong Guo, Yukiko Kiniwa et al. · Science · 2005 · 743 citations

T-regulatory Cell, Immune Regulation, Immunology +23

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

Joshua Brody, Weiyun Z. Ai, Debra K. Czerwinski et al. · Journal of Clinical Oncology · 2010 · 482 citations · Full text

Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod

Tamara L. Wagner, Cory L. Ahonen, Aimee M. Couture et al. · Cellular Immunology · 1999 · 261 citations

Inflammation, Cytokine, Allergy +10

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Alain H. Rook, Joel M. Gelfand, Maria Wysocka et al. · Blood · 2015 · 215 citations · Full text

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Stefanie Mullins, John P. Vasilakos, Katharina Deschler et al. · Journal for ImmunoTherapy of Cancer · 2019 · 200 citations · Full text